EMA Authorised: Ibuprofen Gen.Orph (Ibuprofen) — Gen.Orph

View source ↗

Summary

The European Medicines Agency authorised Ibuprofen Gen.Orph for the treatment of patent ductus arteriosus, with Gen.Orph as the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Patent Ductus Arteriosus

Drugs mentioned

• Ibuprofen Gen.Orph (ibuprofen)

Snippet

Status: Authorised. Therapeutic area: Ductus Arteriosus, Patent. MAH: Gen.Orph. Decision date: 13/02/2026